The current treatment of patients diagnosed with advanced or metastatic head and neck cancer (HNC) is ineffective. Researchers have investigated and validated a potential treatment combination against the aggressive disease driven by hyper-activation of a specific signaling pathway, which is found in over 40 percent of HNC patients.